至本医疗科技（上海）有限公司 () ORIGIMED CO.LTD
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
OrigiMed announced its strategic partnership with Janssen to develop clinical innovative solutions driven by data science 2021-12-03 17:01
The NGS based CDx Human NTRK1/2/3 Genomic Alteration Test Kit to inform treatment decisions for larotrectinib developed by OrigiMed in cooperation with Bayer was granted the NMPA Special Review Procedure for Innovative Medical Devices in China 2021-08-22 09:00
OrigiMed and Takeda Announced Partnership to Accelerate R&D and Commercialization of Innovative Medicines 2020-11-11 21:26
Bayer and OrigiMed reached a partnership to develop a next generation sequencing (NGS) based companion diagnostic-in vitro diagnostic (CDx-IVD) product in China for Larotrectinib, for NTRK gene fusion detection 2020-04-30 10:01
CTONG-OrigiMed New Clinical Trial Sharing Platform Launched during the 3rd OrigiMed Summit for Cancer Discovery 2019-05-24 19:00
OrigiMed Completes Series B Round Focusing on Creating a Comprehensive Precision Medicine Platform for Oncology 2019-01-04 09:30
Launch of Special Chinese Big Data Platform for Cancer Genomics Informatics to Accelerate Innovation and Development of China's Precision Diagnosis and Treatment 2018-09-28 14:04
OrigiMed Collaborates with Illumina to Further Develop and Promote its Advanced Clinical Molecular Tumor Applications 2018-07-13 08:48
1